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Abstract
The impressive selectivity and efﬁcacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent
hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The
recent description of S63845 as the ﬁrst speciﬁc and potent MCL-1 inhibitor represents an important therapeutic advance,
since MCL-1 is not targeted by the currently available BH3 mimetics, Navitoclax or Venetoclax, and is commonly
associated with chemoresistance. In this study, we conﬁrm a high binding afﬁnity and selectivity of S63845 to induce
apoptosis in MCL-1-dependent cancer cell lines. Furthermore, S63845 synergizes with other BH3 mimetics to induce
apoptosis in cell lines derived from both hematological and solid tumors. Although the anti-apoptotic BCL-2 family
members in these cell lines interact with a spectrum of pro-apoptotic BH3-only proteins to regulate apoptosis, these
interactions alone do not explain the relative sensitivities of these cell lines to BH3 mimetic-induced apoptosis. These
ﬁndings necessitated further investigation into the requirement of BH3-only proteins in BH3 mimetic-mediated apoptosis.
Concurrent inhibition of BCL-XL and MCL-1 by BH3 mimetics in colorectal HCT116 cells induced apoptosis in a BAX- but
not BAK-dependent manner. Remarkably this apoptosis was independent of all known BH3-only proteins. Although BH3-
only proteins were required for apoptosis induced as a result of BCL-XL inhibition, this requirement was overcome when
both BCL-XL and MCL-1 were inhibited, implicating distinct mechanisms by which different anti-apoptotic BCL-2 family
members may regulate apoptosis in cancer.
Introduction
Abnormal cell survival through resistance to apoptosis is a
cardinal feature of most malignancies and plays a key role
in chemoresistance. [1, 2] As the major regulators of the
intrinsic mitochondrial pathway of apoptosis, the pro-
survival BCL-2 family proteins (BCL-2, BCL-XL, MCL-
1, and BCL2A1) are attractive targets for novel cancer
therapeutics. [3, 4] These proteins are proposed to function
by binding and sequestering the pro-apoptotic BH3-only
proteins, which in turn prevents the effector proteins, BAX
and BAK, from forming pores in the mitochondrial mem-
brane. The development of inhibitors of the pro-survival
BCL-2 family proteins has proven particularly difﬁcult
because their inhibition requires disruption of these protein-
protein interactions. However, after many years of research,
small molecule inhibitors known as BH3 mimetics, which
target the anti-apoptotic BCL-2 family have now been
developed. The ﬁrst clinically approved BH3 mimetic was
ABT-263 (Navitoclax), an orally available form of
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ABT-737, which inhibits BCL-2, BCL-XL, and BCL-w [3,
5–7] and potently induces apoptosis in several solid and
hematological cancers. This was followed by the introduc-
tion of a BCL-2-speciﬁc inhibitor, ABT-199 (Venetoclax),
which has received approval for treating refractory chronic
lymphocytic leukemia (CLL), where BCL-2 addiction is a
key feature in the pathogenesis of the disease. [8–10]
Recently, BH3 mimetics speciﬁcally targeting BCL-XL (A-
1331852) [11–15] and MCL-1 (A-1210477 and S63845) [1,
12, 16] have also been developed.
In this study, we demonstrate that S63845 is a highly
potent and selective MCL-1 inhibitor, which can synergize
with other BH3 mimetics, including ABT-199 and A-
1331852, to induce apoptosis in a wide range of cell lines
derived from different hematological malignancies and
solid tumors. Furthermore, we demonstrate that BH3-only
proteins are required for apoptosis induced following BCL-
XL inhibition, whereas dual inhibition of BCL-XL
and MCL-1 resulted in a BH3-only protein-independent
cell death.
Materials and methods
Cell culture
Cell lines derived from mantle cell lymphoma (MAVER-1),
diffuse large B cell lymphoma (U-2946), chronic myeloid
leukemia (K562), acute myeloid leukemia (MOLM-13,
OCI-AML-3, HL-60, MV-4-11, THP-1 and U-937), Jurkat-
T-lymphocyte cell lines, wild-type and deﬁcient in caspase-
9 (from Prof. J. Borst, The Netherlands Cancer Institute-
Antoni van Leeuwenhoek, Amsterdam), caspase-8 and
FADD (from Prof. J. Blenis, Weill Cornell Medicine,
USA), non-small cell lung carcinoma (H1299), prostate
cancer (PC-3, from Prof. Y. Ke, University of Liverpool,
UK) and triple negative breast cancer (MDA-MB-231 from
P. Meier, Institute of Cancer Research, London, UK) were
cultured in RPMI 1640 medium. H929, a multiple myeloma
cell line, was cultured in the same medium supplemented
with 0.02% 2-mercaptoethanol. The non-small cell lung
carcinoma cell line A549 was cultured in DMEM/
F12 supplemented with 1% non-essential amino acids. The
pancreatic cancer cell line, SUIT-2 (from A. Mielgo, Uni-
versity of Liverpool, UK) was cultured in DMEM. Colon
cancer cell lines HT-29 (from J. Parsons, University of
Liverpool, UK) and HCT116 (wild-type, DKO and 8KO)
[3, 17–22] as well as HCT116 cells deﬁcient in BAX or
BAK (from R. J. Youle, National Institute of Health, USA),
were cultured in McCoys 5 A Modiﬁed media. All cell
lines, unless otherwise speciﬁed, were either from DMSZ
(Braunshweig, Germany) or ATCC (Middlesex, UK) and
were validated using short tandem repeat proﬁling. Per-
ipheral blood samples from CLL patients were obtained
with patient consent and local ethics committee approval
and cultured as described. [23] All media were supple-
mented with 10% fetal calf serum (Life Technologies Inc.,
Paisley, UK).
Reagents
A-1331852 and A-1210477 from AbbVie Inc. (North
Chicago, IL, USA), S63845 from ActiveBiochem (New
Jersey, USA), and ABT-199 and Z-VAD.FMK from
Selleck Chemicals Co. (Houston, TX, USA) were used.
Antibodies against BCL-XL, BIM and BAD from Cell
Signalling Technology (MA, USA), NOXA from Millipore
(Watford, UK), BID and tubulin from Abcam (Cambridge,
UK), MCL-1, BCL-2 and PUMA from Santa Cruz Bio-
technology (Santa Cruz, CA, USA) and BAX and cyto-
chrome c (BD BioSciences, California) were used for
immunoblotting. Antibodies used for immunoprecipitation
were MCL-1 (Y-37) and BCL-XL from Abcam, BCL-2 from
BD Biosciences and BAX (NT) from Merck-Millipore
(Burlington, MA, USA). siRNAs speciﬁc to BCL-XL
(SI03025141), MCL-1 (SI02781205) and a non-targeting
control (1027310) from Qiagen (Cambridge, UK) were
incubated with Interferin siRNA transfection reagent (Poly-
plus transfection Inc., NY, USA) and added to cells at a
concentration of 10 nM for 72 h.
Differential scanning ﬂuorimetry assay
Thermal shift assays were performed using a StepOnePlus
Real-Time PCR machine (Life Technologies, Paisley, UK)
with Spyro-Orange dye (Invitrogen, Paisley, UK) and pur-
iﬁed recombinant BCL-2 (Abcam) and MCL-1 protein, as
previously described. [3]
Cytochrome c release, BAX translocation and
apoptosis measurements
To quantitate cytochrome c release and BAX translocation,
cells were grown on coverslips and treated with the speci-
ﬁed inhibitors following a 0.5 h pre-treatment with the pan-
caspase inhibitor Z-VAD.FMK (30 μM), and then ﬁxed
with 4% (v/v) paraformaldehyde and permeabilized with
0.5% (v/v) Triton X-100 in PBS, followed by incubation
with primary and ﬂuorophore-conjugated secondary anti-
bodies prior to visualization under a ﬂuorescent microscope.
The extent of cytochrome c released from the mitochondria
or BAX translocation to the mitochondria was quantiﬁed by
counting at least 300 cells from three independent experi-
ments. The extent of apoptosis in cells following different
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treatments was quantiﬁed using an Attune NxT ﬂow cyt-
ometer (Thermo Fisher Scientiﬁc, Paisley, UK), as pre-
viously described. [24]
Gel ﬁltration, immunoprecipitation and Western
blotting
Recombinant MCL-1 puriﬁcation, size exclusion chroma-
tography and immunoprecipitation experiments were car-
ried out as previously described. [3, 25] Western blotting
was carried out according to standard protocols. Brieﬂy,
50 μg of total protein lysate was subjected to SDS-PAGE
electrophoresis. Subsequently proteins were transferred to
nitrocellulose membranes and protein bands visualized with
ECL reagents (GE Healthcare).
Clonogenic studies
Cells were seeded in 6 well plates at a density of 2000 cells/
well and exposed to the speciﬁed inhibitors (100 nM) 24 h
post-seeding. Cells were ﬁxed on day 7 using methanol and
acetic acid and then stained with crystal violet and colonies
counted using the GelCount tumor colony counter (Oxford
Optronix, Abbingdon, UK).
Statistics
For time-course studies, a two-way ANOVA was performed
using Dunnet’s multiple comparisons analysis and other
studies were analyzed for statistical signiﬁcance with one-
way ANOVA using Sidak’s multiple comparisons analysis.
The asterisks depicted correspond to the following p values:
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
Results
S63845 is a potent MCL-1 inhibitor and weak
inducer of apoptosis in BCL-2- but not
BCL-XL-dependent cells
Consistent with previous ﬁndings, [1] we demonstrated that
S63845 is a potent MCL-1 inhibitor when compared with A-
1210477, as assessed by a concentration-dependent thermal
stabilization of MCL-1 in our in vitro thermal shift assay [3]
(Fig. 1a). S63845 also induced rapid apoptosis in two MCL-
1-dependent cell lines (H929 and U-2946), [3, 6] with an
IC50~100 nM, demonstrating ~100-fold higher potency than
A-1210477 (Fig. 1b). To assess the speciﬁcity of S63845 to
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Fig. 1 S63845 binds MCL-1 and induces apoptosis in several cancer
cell lines. a S63845 exhibits a concentration-dependent shift in MCL-1
stabilization in a thermal stability assay. b S63845 and A-1210477
exhibit concentration-dependent apoptosis, as assessed by PS exter-
nalization using ﬂow cytometry, in MCL-1-dependent cell lines, H929
and U-2946 after 4 h of exposure. c S63845 and A-1210477 fail to
induce apoptosis in a BCL-XL-dependent cell line, K562, at 4 h, unlike
A-1331852 (positive control). d MAVER-1, a BCL-2 dependent cell
line, when exposed to the indicated BH3 mimetics for 4 h resulted in
enhanced apoptosis. e Jurkat cells (wild type and deﬁcient in the
speciﬁed proteins), exposed to increasing concentrations of S63845 for
24 h exhibited caspase-9-dependent apoptosis. f Primary cells isolated
from CLL patients, exposed to the indicated BH3 mimetics for 8 h,
exhibited varying extents of apoptosis. g ABT-199 but not S63845
exhibits a concentration-dependent shift in BCL-2 stabilization in a
thermal stability assay. Error bars=Mean ± SEM (standard error of
the mean); *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
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induce apoptosis in a MCL-1 dependent manner, we
exposed K562 cells (a BCL-XL-dependent cell line) and
MAVER-1 cells (a BCL-2-dependent cell line) to increasing
concentrations of S63845 (Fig. 1c, d). As expected, S63845
(as well as A-1210477) failed to induce apoptosis in K562
cells, whereas extensive apoptosis was observed following
exposure to A-1331852 (Fig. 1c). However, S63845 (as well
as A-1210477) induced a concentration dependent increase
in apoptosis in MAVER-1 cells, albeit at higher concentra-
tions than ABT-199 (Fig. 1d), suggesting that S63845 could
either induce death in a non-speciﬁc manner or that it could
also be a weak inhibitor of BCL-2. To test this, we exposed
Jurkat cells (wild type as well as deﬁcient in FADD,
caspase-8 and caspase-9) to increasing concentrations of
S63845. While S63845 induced similar levels of apoptosis
in wild type as well as FADD/ caspase-8 deﬁcient Jurkat
cells, cells deﬁcient in caspase-9 were completely resistant to
S63845-mediated apoptosis (Fig. 1e), thus demonstrating
that S63845 both speciﬁcally induced the intrinsic pathway
of apoptosis and also did not induce non-speciﬁc cell death.
To identify whether S63845, in addition to binding and
inhibiting MCL-1, can also potentially bind and inhibit
BCL-2, we exposed primary CLL cells that exclusively
depend on BCL-2 for survival, [8] to increasing concentra-
tions of S63845 and A-1210477. While ABT-199 (positive
control) induced apoptosis in these cells at low nanomolar
concentrations, both S63845 and A-1210477 also induced
signiﬁcant apoptosis at concentrations similar to their IC50
values in MCL-1 dependent cells (Fig. 1f). However, we did
not detect any concentration-dependent thermal stabilization
of BCL-2 following S63845 in an in vitro thermal shift
assay, which was in marked contrast to the thermal stabili-
zation of BCL-2 following ABT-199 in this assay (Fig. 1g).
Taken together, our data demonstrates that under these
experimental conditions, S63845 does not bind BCL-2 and
induces apoptosis in a MCL-1-speciﬁc manner.
S63845 is more potent than ABT-199 in inducing
apoptosis in AML cell lines
Recent reports indicate that cells derived from acute mye-
loid leukemia (AML) patients can be effectively targeted
with a BCL-2 and/or MCL-1 inhibitor, [11, 13–15]
although other studies suggest that these cells depend pri-
marily on BCL-2 for survival. [16] Indeed, MCL-1 inhibi-
tors are currently entering clinical trials to treat AML and
multiple myeloma patients (Clinical trials—NCT02979366;
NCT02675452; NCT02992483). Therefore, we investigated
whether S63845 alone or in combination with ABT-199
could induce apoptosis in a panel of AML cell lines. Of the
six cell lines tested, MV-4-11 cells exhibited high sensi-
tivity to both S63845 (IC50~20 nM) and ABT-199 (IC50 ~
50-100 nM) individually. THP-1 was much more resistant
to ABT-199 but sensitive to S63845 (IC50~50 nM). OCI-
AML-3, U937 and MOLM-13 were completely resistant to
ABT-199 but somewhat sensitive to S63845 at higher
concentrations. In contrast, HL-60 cells were largely resis-
tant to both BH3 mimetics individually (Fig. 2a). In the
resistant cell lines, particularly U-937 and HL-60, BCL-2
and BCL-XL appeared to perform redundant functions
in cell survival, whereas MOLM-13 cells appeared to
depend on BCL-XL for survival, as exposure to A-1331852
alone resulted in signiﬁcant apoptosis (Supplemental Fig.
S1). Nevertheless, all AML cells examined were more
sensitive to the combination of S63845 and ABT-199
(Fig. 2a).
Interactions between the pro and anti-apoptotic
BCL-2 family members do not reﬂect the relative
sensitivities of AML cell lines to undergo BH3
mimetic-mediated apoptosis
BH3 mimetic-induced apoptosis is usually attributed to
displacement of BH3-only proteins from their anti-apoptotic
partners, leading to apoptosis. Since the different AML cell
lines exhibited varied responses to BH3 mimetic-mediated
apoptosis, we wished to assess if this could be attributed to
altered binding and/or displacement of the different BH3-
only proteins to their known survival counterparts. There-
fore, we immunoprecipitated the anti-apoptotic proteins
required for survival and probed for each of the BH3-only
proteins (Fig. 2b–d). In MV-4-11 cells, which are sensitive
to both ABT-199 and S63845, BIM and PUMA bound to
BCL-2 and were slightly displaced following exposure to
ABT-199 (Fig. 2b). In contrast, the traces of BIM and
NOXA bound to MCL-1 in these cells were readily dis-
placed after S63845 exposure, in-line with the extent of
apoptosis observed with S63845 (IC50~20 nM). Neither
BID nor BAD interacted with MCL-1 or BCL-2 in these
cells (Fig. 2b). In OCI-AML-3, exposure to ABT-199 also
resulted in a partial displacement of BIM and PUMA from
BCL-2, despite the cells being largely resistant to ABT-199
(Fig. 2c). Similar to MV-4-11, BIM and NOXA bound to
MCL-1 were readily displaced with S63845, and BID and
BAD failed to interact with either MCL-1 or BCL-2
(Fig. 2c). In the resistant HL-60 cell line, BIM and PUMA
bound to BCL-2 was not displaced following ABT-199,
compatible with the cells being largely resistant to ABT-199
(Fig. 2d). BID and BAD were not bound to either MCL-1 or
BCL-2. Moreover, of all the BH3-only members, only tra-
ces of NOXA appeared to interact with MCL-1 and was
displaced following S63845 (Fig. 2d). Taken together, these
results suggest that interactions between the pro- and anti-
apoptotic BCL-2 family members may not necessarily
reﬂect the relative sensitivities of different AML cell lines to
undergo BH3 mimetic-mediated apoptosis.
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Interactions of BCL-XL and MCL-1 with different
BH3-only members differ in solid tumor cell lines
Unlike several hematological malignancies, cancer cells
derived from most solid tumors depend on both BCL-XL
and MCL-1 for survival. [3, 17, 19–22] Exposure of cells
derived from a panel of solid tumors, including non-small
cell lung carcinoma (H1299 and A549), pancreas (SUIT-
2), colon (HCT116 and HT-29) and prostate cancer (PC-
3) to a combination of S63845 or A-1331852 resulted in a
marked induction of apoptosis, conﬁrming that these cell
lines depend on both BCL-XL and MCL-1 for survival
(Fig. 3a). To corroborate earlier ﬁndings in AML cell
lines (Fig. 2) in non-hematological cells, we repeated
immunoprecipitation studies and assessed interactions
between the different BH3-only proteins with their key
pro-survival counterparts, namely BCL-XL and MCL-1.
In H1299 cells, BIM and PUMA were preferentially
bound to MCL-1 and BCL-XL, respectively, and were
readily displaced following exposure to the relevant BH3
mimetics (Fig. 3b). This was particularly evident fol-
lowing exposure to S63845, in which the newly released
BIM from the MCL-1 complex exhibited enhanced
binding to BCL-XL. Similarly, exposure to A-1331852
displaced BIM from BCL-XL, which in turn facilitated its
binding to MCL-1 (Fig. 3b). Other BH3-only proteins
like NOXA and BAD exhibited selectivity in binding to
MCL-1 and BCL-XL, respectively and were also dis-
placed after exposure to the relevant BH3 mimetics. No
detectable binding of BID to either BCL-XL or MCL-1
was observed (Fig. 3b). In SUIT-2 cells, BIM was bound
to both MCL-1 and BCL-XL and was displaced to dif-
fering extents with the speciﬁc BH3 mimetics (Fig. 3c).
In contrast to H1299, PUMA was not bound to either
MCL-1 or BCL-XL (Fig. 3c). However, there were some
similarities, especially with NOXA being bound to
MCL-1 and displaced with S63845, and BAD bound to
BCL-XL, which could be disrupted following A-1331852
(Fig. 3c). Therefore, H1299 and SUIT-2 cells exhibit
signiﬁcant differences in their BCL-2 family interaction
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Fig. 2 S63845 can synergize with ABT-199 to induce apoptosis in
AML cell lines. a AML cell lines were exposed to a concentration
range of S63845 with ABT-199 at a constant concentration of 100 nM
for 24 h and assessed for PS externalization. Immunoprecipitation of
MCL-1 and BCL-2 was carried out in b MV-4-11, c OCI-AML-3, and
d HL-60 cells, following exposure to S63845 (30 nM for MV-4-11 and
100 nM for the other 2 cell lines) or ABT-199 (50 nM for MV-4-11
and 100 nM for the other 2 cell lines) for 6 h (MV-4-11) or 8 h (OCI-
AML-3 and HL60). The eluted complexes were immunoblotted for the
indicated proteins. The input represents the cell lysates and BC, beads
control. Error bars=Mean ± SEM; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
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proﬁle, despite similar expression levels of the different
proteins and cell death responsiveness to the combination
of A-1331852 and S63845. This was even more evident
in HCT116 cells, in which most of the BH3-only pro-
teins, with the exception of NOXA, interacted exclu-
sively with BCL-XL, and could be readily displaced from
their binding partners with A-1331852 (Fig. 3d). Col-
lectively, these results suggest that the preferential
sequestration of different BH3-only proteins to distinct
anti-apoptotic counterparts does not solely dictate
dependency of a cell line on an individual anti-apoptotic
protein.
BH3-only proteins are dispensable for BH3
mimetic-induced apoptosis in HCT116 cells
Since BH3-only proteins have recently been demon-
strated to be dispensable for cell death, [18, 26] we
evaluated whether selective inhibitors of BCL-XL and
MCL-1 could induce apoptosis in the absence of all
known BH3-only proteins. Remarkably, in HCT116 8KO
cells, which lack the 8 key BH3-only proteins, BIM, BID,
PUMA, NOXA, HRK, BMF, BIK and BAD, [18] a
combination of S63845 and A-1331852 induced apop-
tosis to the same extent as that of wild-type (WT)
HCT116 cells (Fig. 4a). Furthermore, this combination of
BH3 mimetics resulted in a BAX-dependent but BAK-
independent apoptosis in these cells (Fig. 4b), empha-
sizing a crucial role for BAX in BH3 mimetic-mediated
apoptosis. This raised the possibility of BAX directly
interacting with BCL-XL and/or MCL-1 to antagonize
apoptosis. To test this hypothesis, we immunoprecipi-
tated MCL-1 and BCL-XL complexes from both HCT116
WT and 8KO cells but failed to detect BAX interaction
with either anti-apoptotic protein (Fig. 4c). As a positive
control, we immunoprecipitated active-BAX in these
lysates, which pulled down BAX only following treat-
ment with a combination of S63845 and A-1331852,
indicative of BAX activation during apoptosis (Fig. 4c).
These ﬁndings suggested that the BH3 mimetics could
a
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have displaced other protein(s) distinct from the 8 BH3-
only proteins from BCL-XL and/or MCL-1, which in turn
activated BAX to facilitate mitochondrial outer mem-
brane permeabilization (MOMP) and apoptosis. Apop-
tosis induction in the 8KO cells was accompanied by
translocation of BAX from the cytosol to the mitochon-
drial membrane (Fig. 4d), BAX oligomerization into high
molecular mass complexes as assessed by gel ﬁltration
(Fig. 4e), and MOMP, measured by the release of mito-
chondrial cytochrome c (Fig. 4f). Together, this negates a
role for BH3-only proteins in several critical steps of the
intrinsic apoptotic pathway induced by BH3 mimetics.
Inhibition of BCL-XL and MCL-1 results in
BH3-independent apoptosis
Although many cell lines derived from solid tumors depend
on both BCL-XL and MCL-1 for survival, our studies
revealed that inhibition of BCL-XL following exposure to
A-1331852 was sufﬁcient to induce signiﬁcant apoptosis in
a panel of cell lines (Fig. 5a). To assess whether A-
1331852-mediated apoptosis also occurred in the absence of
all known BH3-only proteins, we employed HCT116 WT
and 8KO cells to assess several hallmarks of apoptosis
following BCL-XL inhibition. Strikingly, exposure to A-
1331852, but not S63845, resulted in enhanced apoptosis,
as assessed by phosphatidylserine (PS) externalization,
MOMP and mitochondrial translocation of BAX in
HCT116 WT but not 8KO cells (Fig. 5b–d) suggesting that
A-1331852-mediated apoptosis requires the presence of
BH3-only proteins. Support for this suggestion was also
provided by the enhanced apoptosis observed in WT, but
not 8KO, cells following siRNA knockdown of BCL-XL
(Fig. 5e). However, this protective effect in 8KO cells was
abolished when both BCL-XL and MCL-1 were down-
regulated, suggesting a requirement of BH3-only proteins in
BCL-XL but not when both BCL-XL and MCL-1 were
downregulated. Similarly, exposure to A-1331852 sig-
niﬁcantly reduced the surviving fraction of WT, but not
8KO, cell populations (Fig. 5f). As expected, S63845 had
no effect on clonogenic survival in either of the cell types,
while a combination of the two BH3 mimetics obliterated
clonogenicity in both cell types (Fig. 5f). Taken together,
our data convincingly argue against the requirement of
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were performed to assess BAX interaction. d The level of
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ferent molecular weight fractions from FPLC showing BAX
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BH3-only proteins in apoptosis regulated by a combination
of both BCL-XL and MCL-1 (Fig. 6).
Discussion
Prior to the discovery of S63845, putative MCL-1 inhi-
bitors were poorly suited for clinical evaluation because
they either lacked potency (high micromolar concentra-
tions were required to inhibit MCL-1) or speciﬁcity
resulting in undesirable toxicity. [3, 24, 27, 28] How-
ever, the development of S63845 potentially strengthens
the use of a wide variety of BH3 mimetics in cancer
therapy. In our hands, S63845 bound MCL-1 more
extensively than A-1210477 and resulted in marked
apoptosis in MCL-1-dependent cell lines (Fig. 1), and
synergized with ABT-199 and A-1331852 to induce
apoptosis in various cancer cell lines (Figs. 2 and 3),
supporting the concept that a potent MCL-1 inhibitor,
such as S63845, could be a valuable addition to the BH3
mimetic armamentarium.
Our ﬁnding that BH3-only proteins are dispensable for
BH3 mimetic-mediated apoptosis in HCT116 cells is
striking, particularly when the proposed mechanism of
action of BH3 mimetics is taken into consideration
(Fig. 4). Since apoptosis induction in these cells still
required BAX and not BAK, [29] it is possible that BH3
mimetics could indirectly activate BAX by disrupting the
interaction of BAX with BCL-XL and/or MCL-1. How-
ever, we could not detect any BAX interaction with either
of these anti-apoptotic proteins, despite efﬁcient mito-
chondrial translocation and oligomerization of BAX,
which resulted in MOMP and PS externalization (Fig. 4).
Failure to detect BAX in complex with anti-apoptotic
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proteins could possibly be due to the dynamic nature of
this interaction. Although BAX is generally considered to
translocate from the cytosol to the outer mitochondrial
membrane following apoptotic stimuli, several reports
suggest a role for the anti-apoptotic BCL-2 family mem-
bers in the constitutive retrotranslocation of BAX from the
mitochondrial outer membrane to the cytosol even under
non-apoptotic conditions. [30–35] Neutralization of the
anti-apoptotic BCL-2 family members with BH3 mimetics
could markedly reduce BAX retrotranslocation to the
cytosol, [33, 36] thus retaining it in the outer mitochon-
drial membrane, which may facilitate direct activation of
BAX (Fig. 6). [18] This could explain the apoptosis
observed following BH3 mimetics in HCT116 cells, even
in the absence of all known BH3-only proteins (Fig. 4).
Our data reveal that the requirement for BH3-only pro-
teins in BCL-XL-regulated apoptosis can clearly be over-
come when both MCL-1 and BCL-XL are inhibited
simultaneously (Figs. 4 and 5). Recent reports have
demonstrated novel interacting partners of MCL-1, such as
the BH3 domain-containing SUFU [37] and VLCAD, [38]
which regulate distinct cellular functions. Therefore, other
BH3-domain containing proteins distinct from the 8 key
BH3-only members could interact with MCL-1 and/or BCL-
XL and play a role in these events (Fig. 6). In summary, our
results demonstrate that BH3 mimetics induce apoptosis
even in the absence of the eight best characterized BH3-only
proteins, while also identifying differences in the regulation
of cell survival by the different anti-apoptotic BCL-2 family
members.. This highlights the need to understand the
Fig. 6 BCL-2 family members differ in their dependence on pro-
apoptotic BH3-only members to exert their anti-apoptotic functions. In
HCT116 cells, multiple BH3-only proteins, such as BIM, BID, BAD
and PUMA are sequestered by BCL-XL, whereas NOXA is the only
BH3-only protein bound to MCL-1. While the displacement of BH3-
only proteins from BCL-XL following A-1331852 is sufﬁcient to
induce apoptosis in these cells, displacement of NOXA from MCL-1
following S63845 failed to induce apoptosis. However, the combina-
tion of A-1331852 and S63845 released all the BH3-only proteins
from the anti-apoptotic counterparts and resulted in pronounced
apoptosis (bold arrow). In the absence of all eight BH3-only proteins,
neither A-1331852 nor S63845 alone resulted in apoptosis. However,
a combination of A-1331852 and S63845 still resulted in pronounced
apoptosis, even in the absence of all BH3-only proteins. This could be
due to the release of another pro-apoptotic BH3 domain-containing
‘protein x’ from MCL-1 and/or BCL-XL, which in turn could activate
BAX in the 8KO cells. Alternatively, BH3 mimetics could indirectly
result in the accumulation of BAX (either by inhibition of retro-
translocation or by passive diffusion, following the neutralization of
the anti-apoptotic members) in the outer mitochondrial membrane,
which in turn could result in BAX activation and apoptosis in the 8KO
cells
BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and. . .
fundamental mechanisms of apoptosis in order to improve
therapeutic approaches using BH3 mimetics.
Acknowledgements We thank AbbVie for providing A-1331852 and
A-1210477. We thank Drs. Youle, Meier, Mielgo, Blenis and Borst for
the different cells used in this study. This work was supported by
North West Cancer Research Grants CR1040 and CR1127 (to SV and
GMC), Science Without Borders, CNPq 233624/2014-7, Ministry of
Education, Brazil (to MM) and NIH Grants R03CA205496 and
R01GM118437 (to XL).
Funding This work was supported by North West Cancer Research
Grant CR1040, CR1127 (to SV and GMC), Science Without Borders,
CNPq 233624/2014-7, Ministry of Education, Brazil (to MM) and
NIH Grants R03CA205496 and R01GM118437 (to XL).
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le
Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable
and effective in diverse cancer models. Nature. 2016;538:477–82.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-
eration. Cell. 2011;144:646–74.
3. Milani M, Byrne DP, Greaves G, Butterworth M, Cohen GM,
Eyers PA, et al. DRP-1 is required for BH3 mimetic-mediated
mitochondrial fragmentation and apoptosis. Cell Death Dis.
2017;8:e2552.
4. Youle RJ, Strasser A. The BCL-2 protein family: opposing
activities that mediate cell death. Nat Rev Mol Cell Biol.
2008;9:47–59.
5. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri
DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 2005;435:677–81.
6. Quentmeier H, Drexler HG, Hauer V, MacLeod RAF, Pommer-
enke C, Uphoff CC, et al. Diffuse large B cell lymphoma cell line
U-2946: model for MCL1 inhibitor testing. PLoS ONE. 2016;11:
e0167599.
7. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S,
et al. ABT-263: a potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 2008;68:3421–8.
8. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD,
Letai A. Chronic lymphocytic leukemia requires BCL2 to
sequester prodeath BIM, explaining sensitivity to BCL2 antago-
nist ABT-737. J Clin Invest. 2007;117:112–21.
9. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND,
Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor,
achieves antitumor activity while sparing platelets. Nat Med.
2013;19:202–8.
10. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD,
Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed
chronic lymphocytic leukemia. N Engl J Med. 2015;374:311–22.
11. Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, et al.
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-
selective inhibitor ABT-199 in acute myeloid leukemia cells.
Signal Transduct Target Ther. 2017;2:17012.
12. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J,
et al. Potent and selective small-molecule MCL-1 inhibitors
demonstrate on-target cancer cell killing activity as single agents
and in combination with ABT-263 (navitoclax). Cell Death Dis.
2015;6:e1590.
13. Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, et al.
Targeting MCL-1/BCL-XL forestalls the acquisition of resistance
to ABT-199 in acute myeloid leukemia. Sci Rep. 2016;6:27696.
14. Teh TC, Nguyen NY, Glaser S, Moujalled D, Pomilio G. Eradi-
cation of acute myeloid leukemia is enhanced by combined Bcl-2
and Mcl-1 targeting. Blood. 2014;124:988.
15. Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M,
et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)
BI97D6 overcomes ABT-737 resistance in acute myeloid leuke-
mia. Blood. 2015;126:363–72.
16. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al.
Selective BCL-2 inhibition by ABT-199 causes on-target cell
death in acute myeloid leukemia. Cancer Discov. 2014;4:362–75.
17. Inoue-Yamauchi A, Jeng PS, Kim K, Chen H-C, Han S, Ganesan
YT, et al. Targeting the differential addiction to anti-apoptotic
BCL-2 family for cancer therapy. Nat Commun. 2017;8:16078.
18. O’Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of
prosurvival Bcl-2 proteins activates Bax/Bak through the outer
mitochondrial membrane. Genes Dev. 2016;30:973–88.
19. Takahashi H, Chen MC, Pham H, Matsuo Y, Ishiguro H, Reber
HA, et al. Simultaneous knock-down of Bcl-xL and Mcl-1 induces
apoptosis through Bax activation in pancreatic cancer cells. Bio-
chim Biophys Acta. 2013;1833:2980–7.
20. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore
SW, et al. Mcl-1 is critical for survival in a subgroup of non-small-
cell lung cancer cell lines. Oncogene. 2010;30:1963–8.
21. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L,
Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective
Bcl-2 proteins and efﬁciently induces apoptosis via Bak/Bax if
Mcl-1 is neutralized. Cancer Cell. 2006;10:389–99.
22. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti
LA, et al. “Seed” analysis of off-target siRNAs reveals an
essential role of Mcl-1 in resistance to the small-molecule Bcl-2/
Bcl-XL inhibitor ABT-737. Oncogene. 2007;26:3972–9.
23. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M,
Dyer MJS, et al. Concurrent up-regulation of BCL-XL
and BCL2A1 induces approximately 1000-fold resistance to
ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:
4403–13.
24. Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky
LD, Cohen GM. Evaluation and critical assessment of putative
MCL-1 inhibitors. Cell Death Differ. 2013;20:1475–84.
25. Lucas CM, Milani M, Butterworth M, Carmell N, Scott LJ, Clark
RE, et al. High CIP2A levels correlate with an antiapoptotic
phenotype that can be overcome by targeting BCL-XL in chronic
myeloid leukemia. Leukemia. 2016;30:1273–81.
26. Delbridge AR, Aubrey BJ, Hyland C, Bernardini JP, Di Rago L,
Garnier J-M, et al. The BH3-only proteins BIM and PUMA
G. Greaves et al.
are not critical for the reticulocyte apoptosis caused by loss of
the pro-survival protein BCL-XL. Cell Death Dis. 2017;8:e2914.
27. Varadarajan S, Poornima P, Milani M, Gowda K, Amin S, Wang
H-G, et al. Maritoclax and dinaciclib inhibit MCL-1 activity and
induce apoptosis in both a MCL-1-dependent and independent
manner. Oncotarget. 2015;6:12668–81.
28. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D,
Cohen GM. Sabutoclax (BI97C1) and BI112D1, putative inhibitors
of MCL-1, induce mitochondrial fragmentation either upstream of
or independent of apoptosis. Neoplasia. 2013;15:568–78.
29. Wang C, Youle RJ. Predominant requirement of Bax for apoptosis
in HCT116 cells is determined by Mcl-1’s inhibitory effect on
Bak. Oncogene. 2011;31:3177–89.
30. Hantusch A, Das KK, García-Sáez AJ, Brunner T, Rehm M. Bax
retrotranslocation potentiates Bcl-xL’s antiapoptotic activity and
is essential for switch-like transitions between MOMP compe-
tency and resistance. Cell Death Dis. 2018;9:430.
31. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang
C, et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into
the cytosol. Cell. 2011;145:104–16.
32. Todt F, Cakir Z, Reichenbach F, Emschermann F, Lauterwasser J,
Kaiser A, et al. Differential retrotranslocation of mitochondrial
Bax and Bak. EMBO J. 2015;34:67–80.
33. Todt F, Cakir Z, Reichenbach F, Youle RJ, Edlich F.
The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation
from the mitochondria. Cell Death Differ. 2013;
20:333–42.
34. Lauterwasser J, Todt F, Zerbes RM, Nguyen TN, Craigen W,
Lazarou M, et al. The porin VDAC2 is the mitochondrial platform
for Bax retrotranslocation. Sci Rep. 2016;6:32994.
35. Schellenberg B, Wang P, Keeble JA, Rodriguez-Enriquez R,
Walker S, Owens TW, et al. Bax exists in a dynamic equilibrium
between the cytosol and mitochondria to control apoptotic prim-
ing. Mol Cell. 2013;49:959–71.
36. Renault TT, Teijido O, Missire F, Ganesan YT, Velours G,
Arokium H, et al. Bcl-xL stimulates Bax relocation to mito-
chondria and primes cells to ABT-737. Int J Biochem Cell Biol.
2015;64:136–46.
37. Wu X, Zhang L-S, Toombs J, Kuo Y-C, Piazza JT, Tuladhar R,
et al. Extra-mitochondrial prosurvival BCL-2 proteins regulate
gene transcription by inhibiting the SUFU tumour suppressor. Nat
Cell Biol. 2017;19:1226–36.
38. Escudero S, Zaganjor E, Lee S, Mill CP, Morgan AM, Crawford
EB, et al. Dynamic regulation of long-chain fatty acid oxidation
by a noncanonical interaction between the MCL-1 BH3 helix and
VLCAD. Mol Cell. 2018;69:729. e7
BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and. . .
